Understanding Elevated Parathyroid Hormone (Elevated PTH) and Hyperparathyroidism is crucial for accurate clinical documentation and medical coding. This resource provides information on diagnosing and managing high PTH levels, including relevant healthcare considerations, symptoms, and treatment options. Learn about the connection between Elevated PTH and Hyperparathyroidism, and ensure proper medical coding for optimal reimbursement. Explore the latest guidelines for documenting Elevated Parathyroid Hormone levels in patient charts.
Also known as
Disorders of parathyroid gland
Includes primary, secondary, and other hyperparathyroidism.
Abnormal findings of blood chemistry
Covers elevated parathyroid hormone levels found during lab testing.
Osteoporosis with pathological fracture
May be a consequence of severe, long-term hyperparathyroidism.
Other abnormal findings in urine
Can include elevated calcium levels related to hyperparathyroidism.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the patient pregnant?
When to use each related code
| Description |
|---|
| High parathyroid hormone levels. |
| Low calcium levels in the blood. |
| High calcium levels in the blood. |
Coding requires specific PTH level documentation to support hyperparathyroidism diagnosis and differentiate from other causes of elevated PTH.
Incorrectly coding primary hyperparathyroidism as secondary, or vice versa, based on inadequate documentation of underlying cause.
Using unspecified codes when clinical documentation supports a more specific hyperparathyroidism diagnosis (e.g., primary, secondary).
Q: What is the differential diagnosis for elevated parathyroid hormone (PTH) levels in asymptomatic patients, and how should I approach it?
A: Elevated parathyroid hormone (PTH) in asymptomatic patients can be caused by primary hyperparathyroidism, secondary hyperparathyroidism (most commonly due to chronic kidney disease or vitamin D deficiency), tertiary hyperparathyroidism (typically in patients with a history of renal transplantation), familial hypocalciuric hypercalcemia (FHH), or certain medications (e.g., lithium). When approaching a patient with asymptomatic hyperparathyroidism, first confirm the hypercalcemia and elevated PTH on repeat testing. Assess the patient's renal function (serum creatinine, estimated glomerular filtration rate) and vitamin D levels (25-hydroxyvitamin D). Measure urinary calcium excretion to differentiate primary hyperparathyroidism from FHH. Consider bone mineral density testing to assess for skeletal involvement. Explore how parathyroid imaging (sestamibi scan or ultrasound) can be used to localize an adenoma in suspected primary hyperparathyroidism. Learn more about the appropriate referral criteria for surgical consultation, especially considering recent guidelines for asymptomatic primary hyperparathyroidism.
Q: How can I differentiate between primary, secondary, and tertiary hyperparathyroidism based on serum calcium, phosphate, PTH, and vitamin D levels?
A: Differentiating between primary, secondary, and tertiary hyperparathyroidism relies on the interplay between serum calcium, phosphate, PTH, and vitamin D levels. In primary hyperparathyroidism, you typically see elevated calcium, normal or low phosphate, and elevated PTH. Vitamin D levels can be normal or low. Secondary hyperparathyroidism is characterized by normal or low calcium, elevated phosphate (especially in chronic kidney disease), elevated PTH, and often low vitamin D. Tertiary hyperparathyroidism develops in patients with long-standing secondary hyperparathyroidism, and presents with elevated calcium, elevated phosphate, and markedly elevated PTH. Vitamin D levels are typically low. Consider implementing a thorough patient history review, including any history of renal disease, to aid in the diagnosis. Explore how using clinical calculators to estimate glomerular filtration rate can contribute to a more accurate diagnosis of secondary hyperparathyroidism.
Patient presents with signs and symptoms suggestive of elevated parathyroid hormone (PTH), also known as hyperparathyroidism. Presenting complaints include fatigue, muscle weakness, bone pain, and kidney stones. Laboratory findings reveal elevated serum calcium levels, elevated intact PTH, and potentially decreased serum phosphorus. Differential diagnosis includes primary hyperparathyroidism, secondary hyperparathyroidism due to chronic kidney disease or vitamin D deficiency, and tertiary hyperparathyroidism. Further evaluation may include bone density scan to assess for osteoporosis or osteopenia, 24-hour urine calcium excretion, and imaging studies such as parathyroid ultrasound or sestamibi scan to localize parathyroid adenoma. Initial treatment plan includes increased fluid intake and monitoring of serum calcium and PTH levels. Referral to an endocrinologist is warranted for further management and consideration of surgical parathyroidectomy, particularly in cases of primary hyperparathyroidism with symptomatic hypercalcemia. ICD-10 code E83.5 (other hyperparathyroidism) or E83.3 (primary hyperparathyroidism) will be used based on diagnostic confirmation. Medical billing will reflect evaluation and management services as well as laboratory and imaging procedures performed. Patient education regarding hyperparathyroidism, dietary modifications, and medication management will be provided. Follow-up appointments are scheduled to monitor disease progression and treatment efficacy.